Status:
ACTIVE_NOT_RECRUITING
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Lead Sponsor:
Peking University
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant t...
Detailed Description
China has the highest incidence and mortality rates of gastric cancer in the world, with approximately 70% of patients diagnosed at an advanced stage. Perioperative treatment combined with surgery is ...
Eligibility Criteria
Inclusion
- Patients have received neoadjuvant therapy and radical resection (R0).
- Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma.
- Patients must be able to provide sufficient fresh tissue/biopsies or minimum 5-10 FFPE sections for NGS-WES analysis.
- Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point.
Exclusion
- Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery.
- Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery.
- Other cases considered unsuitable for inclusion by researchers.
Key Trial Info
Start Date :
April 8 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2027
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT06893133
Start Date
April 8 2025
End Date
April 30 2027
Last Update
June 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China, 100142